Abstract
PPAR³ agonists increase the insulin sensitivity and are used in the treatment of type 2 diabetes mellitus (T2DM). In pancreatic islets, PPAR³ controls insulin secretion, oxidative stress, SR stress and amyloid formation. It is known that the insulin-degrading enzyme (IDE) is the main responsible for the degradation of islet amyloid polypeptide (IAPP), reducing the amyloid formation. Based…